Premium
MALDI‐TOF MS‐based drug susceptibility testing of pathogens: The example of Candida albicans and fluconazole
Author(s) -
Marinach Carine,
Alanio Alexandre,
Palous Martine,
Kwasek Stéphanie,
Fekkar Arnaud,
Brossas JeanYves,
Brun Sophie,
Snounou Georges,
Hennequin Christophe,
Sanglard Dominique,
Datry Annick,
Golmard JeanLouis,
Mazier Dominique
Publication year - 2009
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200900152
Subject(s) - fluconazole , candida albicans , proteome , microbiology and biotechnology , yeast , antifungal , corpus albicans , identification (biology) , computational biology , biology , chemistry , bioinformatics , biochemistry , botany
MALDI‐TOF MS can be used for the identification of microorganism species. We have extended its application to a novel assay of Candida albicans susceptibility to fluconazole, based on monitoring modifications of the proteome of yeast cells grown in the presence of varying drug concentrations. The method was accurate, and reliable, and showed full agreement with the Clinical Laboratory Standards Institute's reference method. This proof‐of‐concept demonstration highlights the potential for this approach to test other pathogens.